Granuloma formation after injection of polycaprolactone dermal filler (case report)
https://doi.org/10.33667/2078-5631-2021-9-94-96
Abstract
A case of clinical observation of a patient with a granulomatous reaction developing in the region of both nasolacrimal grooves after the injection of a filler based on polycaprolactone (PCL) is presented. PCL is used in cosmetology as a filler and collagen synthesis stimulator. It is a biocompatible and biodegradable polymer with a proven safety profile. However, as with the introduction of other types of fillers, in some cases it can cause a granulomatous reaction of varying severity. The clinical observation of this case is of interest to practicing dermatologists, cosmetologists and plastic surgeons.
About the Authors
E. V. Ikonnikova
Central State Medical Academy of the Administrative Department of the President of Russia, Moscow
Russian Federation
Russian Federation
Ikonnikova Evgeniya V.,associate prof. at Dermatovenereology and
Cosmetology Dept
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russia, Moscow
Russian Federation
Russian Federation
Kruglova Larisa S.,DM Sci, prof., head of Dept of Dermatovenereology and Cosmetology. vice-rector for Academic Affairs
References
1. Christen MO, Vercesi F. Polycaprolactone: or how a well-known and futuristic polymer has become an innovative collagen-stimulator in esthetics. Clin Cosmet Investig Dermatol. 2020; 13: 31–48. DOI: 10.2147/CCID.S 229054.
2. Kim JA, Van Abel D. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. Cosmet Laser Ther. 2015; 17 (2): 99–101. DOI: 10.3109/14764172.2014.968586.
3. Morhenn VB, Lemperle G, Gallo RL. Phagocytosis of different particulate dermal filler substances by human macrophages and skin cells. Dermatol Surg. 2002; 28: 484–490. DOI: 10.1046/j.1524–4725.2002.01273.x.
4. de Melo F, Nicolau P, Piovano L, et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone based collagen stimulator (Ellansé®). Clin Cosmet Investig Dermatol. 2017; 10: 431–440. DOI: 10.2147/CCID.S 145195.
5. Carruthers J, Carruthers A, Humphrey S. Introduction to fillers. Plast Reconstr Surg. 2015; 136 (5): 120–131. DOI: 10.1097/PRS.0000000000001770.
6. Gritzalas K. Preliminary results in using a new dermal filler based on poly-caprolactone. Eur J Aesthetic Med Dermatol. 2011; 1 (1): 22–26.
7. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg. 2020; 44 (4): 1348–1360. DOI: 10.1007/s00266–020–01827–7.
8. Laeschke K. Biocompatibility of microparticles into soft tissue fillers. Semin Cutan Med Surg. 2004; 23 (4): 214–217. DOI: 10.1016/j.sder.2004.09.005.
9. Matlaga BF, Yasenchak LP, Salthouse TN. Tissue response to implanted polymers: the significance of sample shape. J Biomed Mater Res. 1976; 10 (3): 391–397. DOI: 10.1002/(ISSN)1097–4636.
10. Wang F, Garza LA, Kang S, et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol. 2007; 143 (2): 155–163. DOI: 10.1001/archderm.143.2.155.
11. Bachir A, Horwitz AR, Nelson WJ, Bianchini JM. Actin-based adhesion modules mediate cell interactions with the extracellular matrix and neighboring cells. Cold Spring Harb Perspect Biol. 2017; 9 (7): a023234. DOI: 10.1101/cshperspect.a023234.
12. Ohashi K, Fujiwara S, Mizuno K. Roles of the cytoskeleton, cell adhesion and rho signalling in mechanosensing and mechanotransduction. J Biochem. 2017; 161 (3): 245–254. DOI: 10.1093/jb/mvw082.
13. Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomized, controlled clinical trial. Dermatol Surg. 2013; 39 (1): 457–463. DOI: 10.1111/dsu.12054.
14. Kim J. Changes in dermal thickness in biopsy study of histologic findings after a single injection of polycaprolactone-based filler into the dermis. Aesthet Surg J. 2019; 39 (12): 484–494. DOI: 10.1093/asj/sjz050.
15. Lemperle G, Duffy DM. Treatment options for dermal filler complications. Aesthet Surg J. 2006; 26 (3): 356–364. DOI: 10.1016/j.asj.2006.04.002.
16. Redaelli A, Rzany B, Eve L, et al. European expert recommendations on the use of injectable poly-L-lactic acid for facial rejuvenation. J Drugs Dermatol. 2014; 13 (9): 1057–1066.
17. Lee JM, Kim YJ. Foreign body granulomas after the use of dermal fillers: pathophysiology, clinical appearance, histologic features, and treatment. Arch Plast Surg. 2015; 42: 232–239. DOI: 10.5999/aps.2015.42.2.232
Review
For citations:
Ikonnikova E.V., Kruglova L.S. Granuloma formation after injection of polycaprolactone dermal filler (case report). Medical alphabet. 2021;(9):94-96. (In Russ.) https://doi.org/10.33667/2078-5631-2021-9-94-96
Views:
936
Email this article 